BiVictriX Therapeutics appoint Dr. Michael Carter as new non-executive director
Acceleris client company BiVictriX Therapeutics are delighted to announce the appointment of Dr. Michael Carter as their new Non-Executive Director. Dr. Michael brings a wealth of experience to BiVictriX and will assist in the next phase of the development of the business.
Dr. MICHAEL G CARTER MB ChB, FRCP (Edin), B.Pharm, DipPharmMed, FRPharm.Soc, FFPM.
45 Years at senior level in the global Pharmaceutical, Biotechnology and Life Sciences Venture Capital industries.
Actively involved in the development and introduction of over 20 innovative new medicines to the world healthcare market, most achieving billion dollar peak year sales status, a majority being cancer focussed.
25years Board level experience with I.C.I Pharmaceuticals (Astra Zeneca) and Roche Products, involving both global clinical development Phase 1 -IV and subsequent global marketing responsibility.
A member of UK Medicines Commission for 10 years, twice reappointed by the Minister of Health.
Awarded Sunday Times Non- Executive Director of the Year 2006 for Private Equity, the first award of such.
In the last 20 years Non- Executive Director/ Chair of circa 20 Biotechnology companies both US and EU with divested returns of over $7Bn.
The first Venture Partner at SV Health Investors 1998-2016 and presently on the Investment Committee and Senior Advisory Board of Healthcare Royalty Partners.